---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-063158"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T17:20:43.270169+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Axsome Q1 total net product revenue $121.5M (+62% YoY); SYMBRAVO launch on track for June 2025

## Summary
- Total net product revenue $121.5M (+62% YoY); AUVELITY $96.2M (+80%) and SUNOSI $25.2M (+17%).
- Net loss improved to $59.4M ($1.22/sh) from $68.4M ($1.44/sh) in Q1 2024; includes $23.3M stock comp.
- SYMBRAVO approved for acute migraine; commercial launch on track for June 2025.
- NDA submitted for AXS-14 (fibromyalgia); sNDA for AXS-05 (AD agitation) on track for Q3 2025; AXS-12 (narcolepsy) NDA in H2 2025.
- Cash $300.9M; company believes sufficient to fund operations to cash flow positivity.

## SEC filing metadata
- accession: 0000950170-25-063158
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/0000950170-25-063158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/axsm-20250505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-063158
- JSON: https://secwatch.observer/filing/0000950170-25-063158.json
- Plain text: https://secwatch.observer/filing/0000950170-25-063158.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.